Everything below concerns Ac-SDKP. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-08. Numbers and descriptions here follow the published literature rather than marketing material.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
In particular, VADAR’s secondary structure assignments appear to agree more closely with secondary structures identified by visual inspection (i.e. author assignments), by STRIDE (another secondary structure assignment algorithm) or via independent methods (i.e. NMR-based NOE methods).
This was an enormous social change, doing much to increase Conservative support amongst new homeowners and which Heseltine often cites as one of his major achievements. Heseltine noted that, "no single piece of legislation has enabled the transfer of so much capital wealth from the state to the people." He said that the 'right to buy' policy had two main objectives: to give people what they had wanted, and to reverse the trend of ever-increasing dominance of the State over the life of the individual. He said: "There is in this country a deeply ingrained desire for home ownership. The Government believe that this spirit should be fostered. It reflects the wishes of the people, ensures the wide spread of wealth through society, encourages a personal desire to improve and modernize one's own home, enables parents to accrue wealth for their children and stimulates the attitudes of independence and self-reliance that are the bedrock of a free society." Many of the homes sold were "street properties" rather than flats, which arguably helped to ghettoise the remaining council tenants on run-down inner city estates. In fact, in Crick's view, he deserves only limited credit; it had been a Conservative commitment since 1974, and much of the detailed work was done by his juniors Hugh Rossi (in opposition) and John Stanley (in government).
=== Crystallization === The structure of β-Amanitin was determined using X-ray crystallography. The crystallization and analysis were performed by Edward C. Kostansek and William H. Lipscomb in 1978. They crystallized β-Amanitin by dissolving a purified sample in almost pure ethanol in a round bottom flask. The flask was left open overnight and crystals formed as the ethanol evaporated. This is considered to be an incredibly easy crystallization to perform.
== History == The concept of electrostatically trapping ions in an orbit around a central spindle was developed by Kenneth Hay Kingdon in the early 1920s. The Kingdon trap consists of a thin central wire and an outer cylindrical electrode. A static applied voltage results in a radial logarithmic potential between the electrodes. In 1981, Knight introduced a modified outer electrode that included an axial quadrupole term that confines the ions on the trap axis. Neither the Kingdon nor the Knight configurations were reported to produce mass spectra. In 1986, Professor Yuri Konstantinovich Golikov in USSR developed theory of ion motion in quadro-logarithmic potential, and filed for patents in USSR for its use in a time-of-flight analyzer. Golikov, leading a team at the St. Petersburg State Pedagogical University's Radiophysics Faculty, laid the theoretical groundwork for Orbitrap technology as one of inventors in USSR Inventor's certificate No. 1247973 in 1986. Golikov later remarked "Based on my ideas, analytical instruments with record parameters were built, but unfortunately not in Russia, but abroad." Contrary to popular belief, Alexander Makarov is not the original inventor of quadro-logarithmic potential which was known since 1950s. Reflecting on his early interaction with Golikov, Alexander Makarov recalled, "As a fifth-year student at MIPT, I entered one of the numerous rooms at the Polytechnic Institute, where I was met by Yuri Konstantinovich Golikov.
Sources: en.wikipedia.org
==== NATO ==== The foreign secretary, Geoffrey Howe, spoke highly of Heseltine's contribution to NATO and WEU conferences. Heseltine was as angry as Thatcher at the US invasion of Grenada, a Commonwealth country. He wanted warmer relations with the Soviets and was sceptical about the US Strategic Defense Initiative ("Star Wars"), putting in a brief and grudging appearance at Caspar Weinberger's Ditchley Park Conference about the topic in 1985. Heseltine came close to misleading the House of Commons over the meeting of NATO defence ministers at Montebello, Quebec, in October 1983. He stated that no "specific" proposals had been made to update NATO short range and tactical nuclear weapons. In fact a decision had been made in principle to do so. Crick describes Heseltine's answers as "highly disingenuous and deceitful". At the time NATO was claiming to be cutting back on such weapons, and the peace movement was still powerful in Germany where such weapons might be used.
== Properties == DTT is oxidized by air. So it is normally stored and handled under inert atmosphere to minimize oxidation. The rate of air-oxidation is slower at low temperatures. Oxidized DTT exhibits a strong absorbance peak at 280 nm. Since thiols are less nucleophilic than their conjugate bases, thiolates, DTT becomes a less potent nucleophile as the pH falls. (2S)-2-Amino-1,4-dimercaptobutane (dithiobutylamine or DTBA), a related dithiol reducing agent, somewhat overcomes this limitation of DTT. Tris(2-carboxyethyl)phosphine (TCEP) is an alternative reducing agent that is more stable and effective at low pH, but it is bulky and reduces cystines in folded proteins only slowly. DTT's half-life is 40 hours at pH 6.5 and 1.4 hours at pH 8.5 and 20 °C; its half-life decreases further as temperature increases. The presence of EDTA (ethylenediaminetetraacetic acid) to chelate divalent metal ions considerably extends the half-life of DTT in solution.
=== START college savings plan === In 1997, Louisiana launched its Student Tuition Assistance and Revenue Trust Savings Program to allow people to start a 529 plan to save for their children's education. As treasurer, Kennedy expanded five new investment options to give parents the choice of investing in the stock market in addition to the fixed returned securities options. He also put these investment options online to make it easier for parents to watch and manage their investments. During Kennedy's tenure, Louisiana's START program was ranked fifth-best in the nation.
They drove into the camp past FRELIMO guards to the parade ground where many were assembled before the attack commenced. The head of the Selous Scouts, Ronald Francis Reid-Daly, claimed that captured ZANLA documents showed that the people killed in the raid were either trained guerrillas or were undergoing guerrilla instruction and training. Paul L. Moorcraft and Peter McLaughlin wrote in 1982, that "although the camp did contain trained guerrillas and young recruits, many of its inhabitants were old people, women and young children who had fled from Rhodesia as refugees". They further wrote in 2010, that "although nearly all the personnel in the camp were unarmed, many were trained guerillas or undergoing instruction" and that documents captured from ZANLA, revealed more than 1,028 were killed in the operation. A 1994 Amnesty International publication described the operation as a massacre and stated that the camp at Nyadzonya housed refugees, and that a soldier who participated in the raid later stated: "We were told that Nyadzonia was a camp containing several thousand unarmed refugees who could be recruited to join the guerrillas. It would be easier if we went in and wiped them out while they were unarmed and before they were trained rather than waiting for the possibility of them being trained and sent back armed into Rhodesia". According to Amnesty International, 1,000 people were killed and the operation was "a gross human rights violation and a war crime".
==== 1.D Non-ribosomally synthesized channels ==== 1.D.1 The Gramicidin A Channel Family 1.D.2 The Channel-forming Syringomycin Family 1.D.3 The Channel-Forming Syringopeptin Family 1.D.4 The Tolaasin Channel-forming Family 1.D.5 The Alamethicin or Peptaibol Antibiotic Channel-forming Family 1.D.6 The Complexed Poly 3-Hydroxybutyrate Ca2+ Channel (cPHB-CC) Family 1.D.7 The Beticolin Family 1.D.8 The Saponin Family 1.D.9 The Polyglutamine Ion Channel (PG-IC) Family 1.D.10 The Ceramide-forming Channel Family 1.D.11 The Surfactin Family 1.D.12 The Beauvericin (Beauvericin) Family 1.D.13 DNA-delivery Amphipathic Peptide Antibiotics (DAPA) 1.D.14 The Synthetic Leu/Ser Amphipathic Channel-forming Peptide (l/S-SCP) Family 1.D.15 The Daptomycin (Daptomycin) Family 1.D.16 The Synthetic Amphipathic Pore-forming Heptapeptide (SAPH) Family 1.D.17 Combinatorially-designed, Pore-forming, β-sheet Peptide Family 1.D.18 The Pore-forming Guanosine-Bile Acid Conjugate Family 1.D.19 Ca2+ Channel-forming Drug, Digitoxin Family 1.D.20 The Pore-forming Polyene Macrolide Antibiotic/fungal Agent (PMAA) Family 1.D.21 The Lipid Nanopore (LipNP) Family 1.D.22 The Proton-Translocating Carotenoid Pigment, Zeaxanthin Family 1.D.23 Phenylene Ethynylene Pore-forming Antimicrobial (PEPA) Family 1.D.24 The Marine Sponge Polytheonamide B (pTB) Family 1.D.25 The Arylamine Foldamer (AAF) Family 1.D.26 The Dihydrodehydrodiconiferyl alcohol 9'-O-β-D-glucoside (DDDC9G) Family 1.D.27 The Thiourea isosteres Family 1.D.28 The Lipopeptaibol Family 1.D.29 The Macrocyclic Oligocholate Family 1.D.30 The Artificial Hydrazide-appended pillar[5]arene Channels (HAPA-C) Family 1.D.31 The Amphotericin B Family 1.D.32 The Pore-forming Novicidin Family 1.D.33 The Channel-forming Polytheonamide B Family 1.D.34 The Channel-forming Oligoester Bolaamphiphiles 1.D.35 The Pore-forming cyclic Lipodepsipeptide Family 1.D.36 The Oligobornene Ion Channel Family 1.D.37 The Hibicuslide C Family 1.D.38 The Cyclic Peptide Nanotube (cPepNT) Family 1.D.39 The Light-controlled Azobenzene-based Amphiphilic Molecular Ion Channel (AAM-IC) Family 1.D.40 The Protein-induced Lipid Toroidal Pore Family 1.D.41 The Sprotetonate-type Ionophore (Spirohexanolide) Family 1.D.42 The Phe-Arg Tripeptide-Pillar[5]Arene Channel (TPPA-C) Family 1.D.43 The Triazole-tailored Guanosine Dinucleoside Channel (TT-GDN-C) Family 1.D.44 The Synthetic Ion Channel with Redox-active Ferrocene (ICRF) Family 1.D.45 The Sonoporation and Electroporation Membrane Pore (SEMP) Family 1.D.46 The DNA Nanopore (DnaNP) Family 1.D.47 The Pore-forming Synthetic Cyclic Peptide (PSCP) Family 1.D.48 The Pore-forming Syringomycin E Family 1.D.49 The Transmembrane Carotenoid Radical Channel (CRC) Family 1.D.50 The Amphiphilic bis-Catechol Anion Transporter (AC-AT) Family 1.D.51 The Protein Nanopore (ProNP) Family 1.D.52 The Aromatic Oligoamide Macrocycle Nanopore (OmnNP) Family 1.D.53 The alpha, gamma-Peptide Nanotube (a,gPepNT) Family 1.D.54 The potassium-selective Hexyl-Benzoureido-15-Crown-5-Ether Ion Channel (HBEC) Family 1.D.55 The Porphyrin-based Nanopore (PorNP) Family 1.D.56 The Alpha-Aminoisobutyrate (Aib) Oligomeric Nanopore (AibNP) Family 1.D.57 The Lipid Electro-Pore (LEP) Family 1.D.58 The Anion Transporting Prodigiosene (Prodigiosene) Family 1.D.59 The Anion Transporting Perenosin (Perenosin) Family 1.D.60 The Alpha,Gamma-Cyclic Peptide (AGCP) Family 1.D.61 The Anionophoric 2,6-Bis(Benzimidazol-2-yl)Pyridine (ABBP) Family 1.D.62 The Bis-Triazolyl DiGuanosine Derivative Channel-forming (TDG) Family 1.D.63 The Peptide-based Nanopore (PepNP) Family 1.D.64 The Carbon Nanotube (CarNT) Family 1.D.65 The Pore-forming Amphidinol (Amphidinol) Family 1.D.66 The Helical Macromolecule Nanopore (HmmNP) Family 1.D.67 The Crown Ether-modified Helical Peptide Ion Channel (CEHP) Family 1.D.68 The Pore-forming Pleuronic Block Polymer (PPBP) Family 1.D.69 The Conical Nanopore (ConNP) Family 1.D.70 The Metallic (Au/Ag/Pt/graphene) Nanopore (MetNP) Family 1.D.71 The Synthetic TP359 Peptide (TP359) Family 1.D.72 The Chloride Carrier Triazine-based Tripodal Receptor (CCTTR) Family 1.D.73 The Mesoporous Silica Nanopore (SilNP) Family 1.D.74 The Stimulus-responsive Synthetic Rigid p-Octiphenyl Stave Pore (SSROP) Family
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.